Legal and Governance Considerations in AI for Drug Discovery: New Paradigms and 2025 Outlook
Just in time for 2025 prediction season, a survey of the emerging AI drug discovery landscape, prepared by Chris Bradbury, …
All Posts
Gilead Sciences and Terray Therapeutics Partner to Advance AI-Driven Small Molecule Drug Discovery
Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has …
Researchers Discover Role of tRNA Fragments in Cancer Progression
A recent study by researchers at Chung-Ang University, South Korea, published in Nature Communications, reveals how a specific transfer RNA-derived …
Candid and EpimAb Collaborate to Develop T-Cell Engagers for Autoimmune Diseases
After debuting with 370$ million capital raise in September 2024, Candid Therapeutics, a San Diego-based biotechnology company specializing in T-cell …
Birmingham Charity Urges Holiday Safety Amid NHS Winter Crisis Talks in the UK
The Royal Society for the Prevention of Accidents (RoSPA) is urging the public to take extra precautions during the festive …
BeiGene Enters Global Licensing Agreement for MAT2A Inhibitor SYH2039 to Expand Solid Tumor Pipeline
BeiGene, Ltd. (NASDAQ: BGNE), a global oncology company soon to be renamed BeOne Medicines Ltd., has announced a global licensing …
Evaxion Biotech Announces Proof-of-Concept for AI-Driven Cancer Vaccines Targeting Endogenous Retrovirus Tumor Antigens
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has announced preclinical Proof-of-Concept (PoC) results for a precision cancer vaccine …
Elevation Oncology Licenses Synaffix ADC Technology for HER3 ADC Development in a $368 Million Deal
Elevation Oncology has entered into a licensing agreement with Synaffix B.V., a Lonza company, to access its antibody-drug conjugate (ADC) …
Relay Therapeutics Shares Updated Interim Data for Novel PI3Kα Inhibitor in Breast Cancer Treatment
Relay Therapeutics, a clinical-stage precision medicine company, has announced updated interim clinical data for its investigational allosteric PI3Kα inhibitor, RLY-2608, …
Insilico Medicine Nominates its 21st Pre-Clinical Candidate: An Orally Available NLRP3 Inhibitor for Inflammation and CNS Diseases
Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced the nomination of its 21st pre-clinical candidate, ISM8969, an …
Xaira Therapeutics Expands Leadership Team and Moves to New Headquarters
Xaira Therapeutics, an integrated biotechnology company focused on leveraging AI to transform drug discovery and development, announced two key appointments …
Relation Therapeutics Partners with GSK to Develop Treatments for Fibrotic Diseases and Osteoarthritis
Relation Therapeutics announced two strategic collaborations with GSK aimed at advancing drug discovery for fibrotic diseases and osteoarthritis, debilitating conditions …